A Recent Study Showed Anticoagulants Enhanced Intracerebral Hemorrhage Outcomes

According to results of the study presented at the 2017 American Academy of Neurology (AAN) Annual Meeting, recommencement of oral anticoagulants following nonlobar and lobar intracerebral hemorrhage (ICH) would result in favorable outcomes and reduction in mortality. The meeting was help in Boston, U.S. during April 22-28, 2017. The post-ICH oral anticoagulation remains a controversial topic. The impact of ICH location on functional outcomes after resuming therapy is yet to be well understood.

Researchers, led by Alessandro Biffi, MD, of Massachusetts General Hospital in Boston conducted a study to understand the effect of ICH locations on outcomes. A meta-analysis of data gathered from three study was conducted. Studies included the OAT-ICH study conducted in Germany (n=542), the multicenter ERICH study (n=217), and a longitudinal primary ICH study conducted in Boston (n=268).

641 patients with nonlobar ICH and 386 patients with lobar ICH were included in the study. All of them were receiving oral anticoagulation treatment. Out of them, 23% of lobar ICH survivors and 28% of nonlobar ICH survivors restarted oral anticoagulation following ICH.

Recommencement of oral anticoagulants was not related to CHADS2 score, ICH volume, or HAS-BLED score (P >.20) in both groups. With patients with lobar ICH, recommencement of oral anticoagulants was related to modified Rankin Scale score at discharge (interquartile range [IQR] 3-5; oral anticoagulation [OA]: median 3.5, no OA: median 4.0, IQR 3-5; P =.011).

Get more details @ https://www.bigmarketresearch.com/request-sample/1166527

After conducting multivariate analyses, recommencement of oral anticoagulants following lobar and nonlobar ICH was related to decreased mortality (lobar: hazard ratio [HR] 0.25, 95% CI, 0.17-0.38; P <.0001; nonlobar: HR 0.22, 95% CI, 0.16-0.30; P <.0001) and enhancement in functional outcomes (lobar: HR 4.89, 95% CI, 3.25-7.36; P <.0001; nonlobar: HR 5.12, 95% CI, 3.86-6.80; P <.0001) after a follow-up of a year. Researchers concluded that results help future investigations to determine benefits and risks of oral anticoagulant recommencement after ICH.

The recent studies and researches show how anticoagulants would bring changes in some of the health conditions. It would help market players in determining opportunities and capitalize on them to gain strong position in the market. In its recent report on the North America anticoagulants market, Big Market Research outlines current market status, key vendors, and geographical scenario. Sales, revenue, and growth rate of the leading market players is provided in the study to help in determining competitive landscape and devising strategies for the future. Detailed segmentation, marketing strategies, and sales channels are also offered.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com